Enzene Biosciences

Enzene Biosciences, founded in 2014 and headquartered in Alameda, USA, is an innovation-driven biotech and CDMO with a core focus on biosimilars and advanced manufacturing. Its key differentiator is the EnzeneX™ platform, a patented continuous bioprocessing technology designed to significantly lower production costs for complex biologics like monoclonal antibodies. The company operates a dual business model, offering end-to-end CDMO services to third parties while also developing its own pipeline of biosimilar products for licensing, positioning it to impact the global healthcare landscape through cost-effective biologics.

EnzeneX™ - a patented and validated continuous bioprocess manufacturing platform for biologics, designed to drastically reduce production costs for monoclonal antibodies and complex proteins.

Enzene competes with large, established CDMOs (e.g., Lonza, Samsung Biologics, Fujifilm Diosynth) and other biosimilar developers. Its primary competitive differentiation is the cost and efficiency advantage of its proprietary EnzeneX™ continuous manufacturing platform, which is less common at commercial scale in the industry.